Featured Content

  • Wednesday’s Small Cap Biotech Catalyst Watch And Trade List Below, I have listed 5 biotechs with near-term fundamental catalysts that should see their respective prices on the move. I also list the chart for each company and offer my price target opinions based on both the fundamental catalyst and technical indicators.
  • Medivation’s Xtandi Threatened by J&J’s New Acquisition One of the biotech laggards of the year, Medivation (NASDAQ: MDVN) saw a very high volume selloff (-6.78% ▼$47.41/share) yesterday after rival Johnson & Johnson (NYSE: JNJ) announced the acquisition of Aragon Pharmaceuticals – a company that was developing a Phase II metastatic castration-resistant prostate cancer (mCRPC) drug that the market considers a threat to Xtandi - Medivation’s lone pipeline drug.
  • Biodel Primed To Capitalize On Next Generation Treatments In The $10B Diabetes Market Glucose is one of the most important chemical structures because it is essential in providing the body with energy. It is integral in the chemical process called aerobic respiration, which generates a usable form of energy. Glycolysis is the beginning of this process, which oxidizes glucose to form CO2, H20, and adenosine triphosphate (ATP).
More News

Subscriber Only Content

More News

Sector News

More News


More Articles...
<< Start < 271 272 273 274 276 278 279 280 > End >>

Page 276 of 800
BioMedReports Fate of the heart: Researchers track cellular events leading to cardiac regeneration http://t.co/nVOQUUo3Nx
2hreplyretweetfavorite
BioMedReports Healthcare Review: Pluristem Therapeutics, Vanda Pharmaceuticals, VIVUS, Protalix BioTherapeutics, Keryx Bioph... http://t.co/hivVPXDMZn
5hreplyretweetfavorite
BioMedReports Wednesday’s Small Cap Biotech Catalyst Watch And Trade List: Below, I have listed 5 biotechs with near-term f... http://t.co/xf5K723eVw
11hreplyretweetfavorite
navigation
Benzinga.com supporter Seeking Alpha Certified

RSS Subscription